Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
ORION OYJ |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 36.24 EUR | +0.36% | -0.55% | -29.27% | |
| Nov. 21 | Orion Corporation Announces Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov Database | CI |
| Nov. 20 | Orion Unit Gets US FDA Approval for Animal Anxiety Medicine | MT |
| Sales 2023 * | 1.18B 1.28B | Sales 2024 * | 1.29B 1.39B | Capitalization | 5.08B 5.48B |
|---|---|---|---|---|---|
| Net income 2023 * | 191M 206M | Net income 2024 * | 237M 256M | EV / Sales 2023 * | 4,23x |
| Net cash position 2023 * | 66.86M 72.14M | Net cash position 2024 * | 106M 114M | EV / Sales 2024 * | 3,86x |
| P/E ratio 2023 * | 26,7x | P/E ratio 2024 * | 21,5x | Employees | 3,574 |
| Yield 2023 * | 4,46% | Yield 2024 * | 4,64% | Free-Float | 88.69% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.36% | ||
| 1 week | -0.71% | ||
| Current month | -0.55% | ||
| 1 month | -1.66% | ||
| 3 months | -3.31% | ||
| 6 months | -9.99% | ||
| Current year | -29.27% |
1 week
35.84
36.92
1 month
35.8438.06
Current year
32.8955.16
1 year
32.8955.16
3 years
32.5155.16
5 years
28.1955.16
10 years
18.6158.50
| Managers | Title | Age | Since |
|---|---|---|---|
Liisa Hurme
CEO | Chief Executive Officer | 56 | 1998 |
| Director of Finance/CFO | 62 | 2000 | |
Outi Vaarala
CTO | Chief Tech/Sci/R&D Officer | 61 | 2020 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 2014 | |
| Director/Board Member | 62 | 2021 | |
| Director/Board Member | 60 | 2017 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.96% | 1,332 M€ | +0.41% | ||
| 1.92% | 2 M€ | +5.80% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-07 | 36.24 | +0.36% | 222,676 |
| 23-12-05 | 36.11 | -0.74% | 256,087 |
| 23-12-04 | 36.38 | -0.30% | 139,525 |
| 23-12-01 | 36.49 | +0.14% | 164,972 |
| 23-11-30 | 36.44 | -0.16% | 832,259 |
Delayed Quote Nasdaq Helsinki, December 07, 2023 at 11:29 am EST
More quotes
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (48.3%);
- patented prescription products (37.3%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- pharmaceutical ingredients and outsourcing services (7.2%) ;
- animal products (7%);
- other (0.2%).
Net sales are distributed geographically as follows: Finland (30.3%), Scandinavia (13.6%), Europe (34%), North America (8.6%) and other (13.5%).
Sector
Pharmaceuticals
Calendar
2024-02-13
- Q4 2023 Earnings Release
Trading Rating :
Investor Rating :
ESG Refinitiv :
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
36.24EUR
Average target price
42.52EUR
Spread / Average Target
+17.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.27% | 5 468 M $ | |
| +60.80% | 530 B $ | |
| +42.05% | 438 B $ | |
| -12.03% | 377 B $ | |
| -6.37% | 268 B $ | |
| -8.44% | 258 B $ | |
| -14.13% | 230 B $ | |
| +0.79% | 200 B $ | |
| -9.98% | 198 B $ | |
| -44.13% | 163 B $ |
